FGFR Signaling Promotes the Growth of Triple-Negative and Basal-Like Breast Cancer Cell Lines Both <i>In Vitro</i> and <i>In Vivo</i>

Rachel Sharpe(Guy's Hospital), Nicholas C. Turner(Institute of Cancer Research), María Teresa Herrera-Abreu(Institute of Cancer Research), Rachael Natrajan(Institute of Cancer Research), Alan Mackay(Institute of Cancer Research), Jorge S. Reis‐Filho(AstraZeneca (France)), Andrew R. Reynolds(Breast Cancer Now), Alan Ashworth(University of California, San Francisco), Jonathan Welti(Institute of Cancer Research), Damian Johnson(Institute of Cancer Research), Alex Pearson(Breast Cancer Now)
Clinical Cancer Research
June 28, 2011
10.1158/1078-0432.ccr-10-2727
Cited by 170

Related Papers

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
|New England Journal of Medicine|2015|1.6k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
|New England Journal of Medicine|2018|1.3k
Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma
|Cancer Cell|2017|1.3k